Top

08-05-2018 | Gout | Review | Article

An update on the genetics of hyperuricaemia and gout

Journal: Nature Reviews Rheumatology

Authors: Tanya J. Major, Nicola Dalbeth, Eli A. Stahl, Tony R. Merriman

Publisher: Nature Publishing Group UK

Abstract

A central aspect of the pathogenesis of gout is elevated urate concentrations, which lead to the formation of monosodium urate crystals. The clinical features of gout result from an individual's immune response to these deposited crystals. Genome-wide association studies (GWAS) have confirmed the importance of urate excretion in the control of serum urate levels and the risk of gout and have identified the kidneys, the gut and the liver as sites of urate regulation. The genetic contribution to the progression from hyperuricaemia to gout remains relatively poorly understood, although genes encoding proteins that are involved in the NLRP3 (NOD-, LRR- and pyrin domain-containing 3) inflammasome pathway play a part. Genome-wide and targeted sequencing is beginning to identify uncommon population-specific variants that are associated with urate levels and gout. Mendelian randomization studies using urate-associated genetic variants as unconfounded surrogates for lifelong urate exposure have not supported claims that urate is causal for metabolic conditions that are comorbidities of hyperuricaemia and gout. Genetic studies have also identified genetic variants that predict responsiveness to therapies (for example, urate-lowering drugs) for treatment of hyperuricaemia. Future research should focus on large GWAS (that include asymptomatic hyperuricaemic individuals) and on increasing the use of whole-genome sequencing data to identify uncommon genetic variants with increased penetrance that might provide opportunities for clinical translation.

Dalbeth, N., Merriman, T. R. & Stamp, L. K. Gout. Lancet 388, 2039–2052 (2016).PubMedCrossRef

Zhu, Y., Pandya, B. J. & Choi, H. K. Prevalence of gout and hyperuricemia in the US general population: the national health and nutrition examination survey 2007–2008. Arthritis Rheum. 63, 3136–3141 (2011).PubMedCrossRef

Richette, P., Clerson, P., Perissin, L., Flipo, R. M. & Bardin, T. Revisiting comorbidities in gout: a cluster analysis. Ann. Rheum. Dis. 74, 142–147 (2015).PubMedCrossRef

Robinson, P. C. & Hosburgh, S. Gout: joints and beyond, epidemiology, clinical features, treatment and co-morbidities. Maturitas 78, 245–251 (2014).PubMedCrossRef

Merriman, T. R. An update on the genetic architecture of hyperuricemia and gout. Arthritis Res. Ther. 17, 98 (2015).PubMedPubMedCentralCrossRef

Campion, E. W., Glynn, R. J. & DeLabry, L. O. Asymptomatic hyperuricemia. risks and consequences normative aging study. Am. J. Med. 82, 421–426 (1987).PubMedCrossRef

Krishnan, E., Lessov-Schlaggar, C. N., Krasnow, R. E. & Swan, G. E. Nature versus nurture in gout: a twin study. Am. J. Med. 125, 499–504 (2012).PubMedCrossRef

Kalousdian, S., Fabsitz, R., Havlik, R., Christian, J. & Rosenman, R. Heritability of clinical chemistries in an older twin cohort: the NHLBI Twin Study. Genet. Epidemiol. 4, 1–11 (1987).PubMedCrossRef

Whitfield, J. & Martin, N. Inheritance and alcohol as factors influencing plasma uric acid levels. Acta Genet. Med. Gemello 32, 117–126 (1983).CrossRef

10.

Emmerson, B. T., Nagel, S. L., Duffy, D. L. & Martin, N. G. Genetic control of the renal clearance of urate: a study of twins. Ann. Rheum. Dis. 51, 375–377 (1992).PubMedPubMedCentralCrossRef

11.

Monga, M., Macias, B., Groppo, E. & Hargens, A. Genetic heritability of urinary stone risk in identical twins. J. Urol. 175, 2125–2128 (2006).PubMedCrossRef

12.

Nilsson, S. E., Read, S., Berg, S. & Johansson, B. Heritabilities for fifteen routine biochemical values: findings in 215 Swedish twin pairs 82 years of age or older. Scan. J. Clin. Lab. Invest. 69, 562–569 (2009).CrossRef

13.

Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-wide complex trait analysis. Am. J. Hum. Genet. 88, 76–82 (2010).PubMedCrossRef

14.

Kottgen, A. et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat. Genet. 45, 145–154 (2013).PubMedCrossRef

15.

Cadzow, M., Merriman, T. R. & Dalbeth, N. Performance of gout definitions for genetic epidemiological studies: analysis of UK Biobank. Arthritis Res. Ther. 19, 181 (2017).PubMedPubMedCentralCrossRef

16.

Perez-Ruiz, F., Calabozo, M., Erauskin, G. G., Ruibal, A. & Herrero-Beites, A. M. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum. 47, 610–613 (2002).PubMedCrossRef

17.

Ichida, K. et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat. Comm. 3, 764 (2012).CrossRef

18.

Khanna, D. et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic non-pharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 64, 1431–1436 (2012).CrossRef

19.

Richette, P. et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann. Rheum. Dis. 76, 29–42 (2017).PubMedCrossRef

20.

Stamp, L. K. et al. Impaired response or insufficient dosage? Examining the potential causes of “inadequate response” to allopurinol in the treatment of gout. Semin. Arthritis Rheum. 44, 170–174 (2014).PubMedPubMedCentralCrossRef

21.

Dalbeth, N. et al. Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study. Ann. Rheum. Dis. 74, 908–911 (2015).PubMedCrossRef

22.

Roddy, E., Zhang, W. & Doherty, M. Are joints affected by gout also affected by osteoarthritis? Ann. Rheum. Dis. 66, 1374–1377 (2007).PubMedPubMedCentralCrossRef

23.

Dalbeth, N. et al. Tendon involvement in the feet of patients with gout: a dual-energy CT study. Ann. Rheum. Dis. 72, 1545–1548 (2013).PubMedCrossRef

24.

Chhana, A., Lee, G. & Dalbeth, N. Factors influencing the crystallization of monosodium urate: a systematic literature review. BMC Musculoskelet. Disord. 16, 296 (2015).PubMedPubMedCentralCrossRef

25.

Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237–241 (2006).PubMedCrossRef

26.

Dalbeth, N. et al. Cellular characterization of the gouty tophus: a quantitative analysis. Arthritis Rheum. 62, 1549–1556 (2010).PubMedCrossRef

27.

Gibson, T., Waterworth, R., Hatfield, P., Robinson, G. & Bremner, K. Hyperuricaemia, gout and kidney function in New Zealand Maori men. Br. J. Rheumatol. 23, 276–282 (1984).PubMedCrossRef

28.

Okada, Y. et al. Meta-analysis identifies multiple loci associated with kidney function-related traits in east Asian populations. Nat. Genet. 44, 904–909 (2012).PubMedPubMedCentralCrossRef

29.

Tin, A. et al. Genome-wide association study for serum urate concentrations and gout among African Americans identifies genomic risk loci and a novel URAT1 loss-of-function allele. Hum. Mol. Genet. 20, 4056–4068 (2011).PubMedPubMedCentralCrossRef

30.

Dehghan, A. et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet 372, 1953–1961 (2008).PubMedPubMedCentralCrossRef

31.

Li, C. et al. Genome-wide association analysis identifies three new risk loci for gout arthritis in Han Chinese. Nat. Comm. 6, 7041 (2015).CrossRef

32.

Li, Z. et al. Replication of gout/urate concentrations GWAS susceptibility loci associated with gout in a Han Chinese population. Sci. Rep. 7, 4094 (2017).PubMedPubMedCentralCrossRef

33.

Matsuo, H. et al. Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes. Ann. Rheum. Dis. 75, 652–659 (2016).PubMedCrossRef

34.

Phipps-Green, A. J. et al. Twenty-eight loci that influence serum urate levels: analysis of association with gout. Ann. Rheum. Dis. 75, 124–130 (2016).PubMedCrossRef

35.

Urano, W. et al. Effect of genetic polymorphisms on development of gout. J. Rheumatol. 40, 1374–1378 (2013).PubMedCrossRef

36.

Batt, C. et al. Sugar-sweetened beverage consumption: a risk factor for prevalent gout with SLC2A9 genotype-specific effects on serum urate and risk of gout. Ann. Rheum. Dis. 73, 2101–2106 (2013).PubMedPubMedCentralCrossRef

37.

McKinney, C. et al. Multiplicative interaction of functional inflammasome genetic variants in determining the risk of gout. Arthritis Res. Ther. 17, 288 (2015).PubMedPubMedCentralCrossRef

38.

Rasheed, H., Stamp, L. K., Dalbeth, N. & Merriman, T. R. Interaction of the GCKR and A1CF loci with alcohol consumption to influence the risk of gout. Arthritis Res. Ther. 19, 161 (2017).PubMedPubMedCentralCrossRef

39.

Rasheed, H. et al. Association of the lipoprotein receptor-related protein 2 gene with gout and non-additive interaction with alcohol consumption. Arthritis Res. Ther. 15, R177 (2013).PubMedPubMedCentralCrossRef

40.

Scharpf, R. B. et al. Copy number polymorphisms near SLC2A9 are associated with serum uric acid concentrations. BMC Genet. 15, 81 (2014).PubMedPubMedCentralCrossRef

41.

Higashino, T. et al. Multiple common and rare variants of ABCG2 cause gout. RMD Open 3, e000464 (2017).PubMedPubMedCentralCrossRef

42.

Stiburkova, B. et al. Functional non-synonymous variants of ABCG2 and gout risk. Rheumatology 56, 1982–1992 (2017).PubMedCrossRef

43.

Boocock, J. et al. Trans-ancestral meta-analysis identifies nine new loci associated with serum uric acid concentrations [abstract]. Arthritis Rheumatol. 68 (Suppl. 10), 2273 (2016).

44.

Merriman, T. R., Choi, H. K. & Dalbeth, N. The genetic basis of gout. Rheum. Dis. Clin. North Am. 40, 279–290 (2014).PubMedCrossRef

45.

Boyle, E. A., Li, Y. I. & Pritchard, J. K. An expanded view of complex traits: from polygenic to omnigenic. Cell 169, 1177–1186 (2017).PubMedCrossRefPubMedCentral

46.

Doring, A. et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat. Genet. 40, 430–436 (2008).PubMedCrossRef

47.

Vitart, V. et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat. Genet. 40, 437–442 (2008).PubMedCrossRef

48.

Cleophas, M. et al. ABCG2 polymorphisms in gout: insights into disease susceptibility and treatment approaches. Pharmacogenomics Pers. Med. 10, 129–142 (2017).CrossRef

49.

Merriman, T. R. et al. Non-coding genetic variant maximally associated with serum urate levels is functionally linked to HNF4A-dependent PDZK1 expression [abstract]. Arthritis Rheumatol. 69, S10 (2017).

50.

Beer, N. L. et al. The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum. Mol. Genet. 18, 4081–4088 (2009).PubMedPubMedCentralCrossRef

51.

Rees, M. et al. Cellular characterisation of the GCKR P446L variant associated with type 2 diabetes risk. Diabetologia 55, 114–122 (2012).PubMedCrossRef

52.

Sakiyama, M. et al. Identification of rs671, a common variant of ALDH2, as a gout susceptibility locus. Sci. Rep. 6, 25360 (2016).PubMedPubMedCentralCrossRef

53.

Sulem, P. et al. Identification of low-frequency variants associated with gout and serum uric acid levels. Nat. Genet. 43, 1127–1130 (2011).PubMedCrossRef

54.

Shin, J., Kim, Y., Kong, M. & Lee, C. Genetic architecture for susceptibility to gout in the KARE cohort study. J. Hum. Genet. 57, 379–384 (2012).PubMedCrossRef

55.

Kuo, J. Z. et al. Trans-ethnic fine mapping identifies a novel independent locus at the 3^' end of CDKAL1 and novel variants of several susceptibility loci for type 2 diabetes in a Han Chinese population. Diabetologia 56, 2619–2628 (2013).PubMedPubMedCentralCrossRef

56.

Nakayama, A. et al. GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes. Ann. Rheum. Dis. 76, 869–877 (2017).PubMedCrossRef

57.

Li, C. et al. Genetic variants associated with tophi occurrence by a genome wide association study of 1888 patients. Gout and Hyperuricemia 4, 12–20 (2017).CrossRef

58.

Merriman, T. R. et al. Genome-wide association study of gout in people of European ancestry [abstract]. Arthritis Rheumatol. 69, S10 (2017).

59.

Vasiliou, V. et al. ALDH16A1 is a novel non-catalytic enzyme that may be involved in the etiology of gout via protein–protein interactions with HPRT1. Chem. Biol. Interact. 202, 22–31 (2013).PubMedPubMedCentralCrossRef

60.

Charkoftaki, G. et al. Transcriptomic analysis and plasma metabolomics in Aldh16a1-null mice reveals a potential role of ALDH16A1 in renal function. Chem. Biol. Interact. 276, 15–22 (2017).PubMedPubMedCentralCrossRef

61.

Hollis-Moffatt, J. E. et al. The renal urate transporter SLC17A1 locus: confirmation of association with gout. Arthritis Res. Ther. 14, R92 (2012).PubMedPubMedCentralCrossRef

62.

Tanner, C. et al. Population-specific resequencing associates the ATP-binding cassette subfamily C member 4 gene with gout in New Zealand Māori and Pacific men. Arthritis Rheumatol. 69, 1461–1469 (2017).PubMedCrossRefPubMedCentral

63.

Farrés, J. et al. Effects of changing glutamate 487 to lysine in rat and human liver mitochondrial aldehyde dehydrogenase. A model to study human (Oriental type) class 2 aldehyde dehydrogenase. J. Biol. Chem. 269, 13854–13860 (1994).PubMed

64.

Yamanaka, H. et al. Analysis of the genotypes for aldehyde dehydrogenase 2 in Japanese patients with primary gout. Adv. Exp. Med. Biol. 370, 53–56 (1994).PubMedCrossRef

65.

Qing, Y. F. et al. Association of TLR4 gene rs2149356 polymorphism with primary gouty arthritis in a case-control study. PLoS ONE 8, e64845 (2013).PubMedPubMedCentralCrossRef

66.

Rasheed, H. et al. The Toll-like receptor 4 (TLR4) variant rs2149356 and risk of gout in European and Polynesian sample sets. PLoS ONE 11, e0147939 (2016).PubMedPubMedCentralCrossRef

67.

Chen, Y. et al. CARD 8 rs2043211 polymorphism is associated with gout in a Chinese male population. Cell. Physiol. Biochem. 35, 1394–1400 (2015).PubMedCrossRef

68.

Landvik, N. E. et al. A specific interleukin-1B haplotype correlates with high levels of IL1B mRNA in the lung and increased risk of non-small cell lung cancer. Carcinogenesis 30, 1186–1192 (2009).PubMedCrossRef

69.

Delgado-Lista, J. et al. Interleukin 1B variant-1473G/C (rs1143623) influences triglyceride and interleukin 6 metabolism. J. Clin. Endocrinol. Metab. 96, E816–E820 (2011).PubMedPubMedCentralCrossRef

70.

Chang, W. C. et al. Genetic variants of PPAR-gamma coactivator 1B augment NLRP3-mediated inflammation in gouty arthritis. Rheumatology 56, 457–466 (2017).PubMed

71.

Shaukat, A. et al. Replication of genetic association of peroxisome proliferator-activated receptor gamma-1B with gout in a New Zealand Polynesian sample set [abstract]. Arthritis Rheumatol. 69 (Suppl. 10), 1127 (2017).

72.

Gosling, A. L. et al. Mitochondrial genetic variation and susceptibility to gout in Maori and Pacific people living in Aotearoa New Zealand. Ann. Rheum. Dis. 77, 571–578 (2017).PubMedCrossRef

73.

Merriman, T. & Terkeltaub, R. PPARGC1B: insight into the expression of the gouty inflammation phenotype: PPARGC1B and gouty inflammation. Rheumatology 56, 323–325 (2017).PubMed

74.

Cardona, F. et al. Contribution of polymorphisms in the apolipoprotein AI-CIII-AIV cluster to hyperlipidaemia in patients with gout. Ann. Rheum. Dis. 64, 85–88 (2005).PubMedCrossRef

75.

Rasheed, H. et al. Replication of association of the apolipoprotein A1-C3-A4 gene cluster with the risk of gout. Rheumatology 55, 1421–1430 (2016).PubMedPubMedCentralCrossRef

76.

Hyka, N. et al. Apolipoprotein AI inhibits the production of interleukin-1β and tumor necrosis factor-α by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 97, 2381–2389 (2001).PubMedCrossRef

77.

Chiang, S. et al. Increased level of MSU crystal-bound protein apolipoprotein AI in acute gouty arthritis. Scand. J. Rheumatol. 43, 498–502 (2014).PubMedCrossRef

78.

CriȘan, T. O. et al. Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra. Ann. Rheum. Dis. 75, 755–762 (2016).PubMedCrossRef

79.

Dong, Z. et al. Effects of multiple genetic loci on the pathogenesis from serum urate to gout. Sci. Rep. 7, 43614 (2017).PubMedPubMedCentralCrossRef

80.

Merriman, T. R. et al. Pleiotropic effect of ABCG2 in gout [abstract]. Arthritis Rheumatol. 68 (Suppl. 10), 2276 (2016).

81.

Basseville, A. et al. Histone deacetylase inhibitors influence chemotherapy transport by modulating expression and trafficking of a common polymorphic variant of the ABCG2 efflux transporter. Canc. Res. 72, 3642–3651 (2012).CrossRef

82.

Wang, J. et al. Association between gout and polymorphisms in GCKR in male Han Chinese. Hum. Genet. 131, 1261–1265 (2012).PubMedCrossRef

83.

Kanbay, M. et al. Uric acid in metabolic syndrome: from an innocent bystander to a central player. Eur. J. Intern. Med. 29, 3–8 (2016).PubMedCrossRef

84.

Robinson, P. C., Choi, H. K., Do, R. & Merriman, T. R. Insight into rheumatological cause and effect through the use of Mendelian randomization. Nat. Rev. Rheumatol. 12, 486–496 (2016).PubMedCrossRef

85.

Hughes, K., Flynn, T., de Zoysa, J., Dalbeth, N. & Merriman, T. R. Mendelian randomization analysis associates increased serum urate, due to genetic variation in uric acid transporters, with improved renal function. Kidney Int. 85, 344–351 (2014).PubMedCrossRef

86.

Lyngdoh, T. et al. Serum uric acid and adiposity: deciphering causality using a bidirectional Mendelian randomization approach. PLoS ONE 7, e39321 (2012).PubMedPubMedCentralCrossRef

87.

Rasheed, H., Hughes, K., Flynn, T. J. & Merriman, T. R. Mendelian randomization provides no evidence for a causal role of serum urate in increasing serum triglyceride levels. Circ. Cardiovasc. Genet. 7, 830–837 (2014).PubMedPubMedCentralCrossRef

88.

Palmer, T. M. et al. Association of plasma uric acid with ischaemic heart disease and blood pressure: Mendelian randomisation analysis of two large cohorts. Br. Med. J. 347, f4262 (2013).CrossRef

89.

Keenan, T. et al. Causal assessment of serum urate levels in cardiometabolic diseases through a Mendelian randomization study. J. Am. Coll. Cardiol. 67, 407–416 (2016).PubMedPubMedCentralCrossRef

90.

Sluijs, I. et al. A Mendelian randomization study of circulating uric acid and type 2 diabetes. Diabetes 64, 3028–3036 (2015).PubMedCrossRef

91.

White, J. et al. Plasma urate concentration and risk of coronary heart disease: a Mendelian randomisation analysis. Lancet Diabetes Endocrinol. 4, 327–336 (2016).PubMedPubMedCentralCrossRef

92.

Dalbeth, N., Stamp, L. K. & Merriman, T. R. The genetics of gout: towards personalised medicine? BMC Med. 15, 108 (2017).PubMedPubMedCentralCrossRef

93.

Ko, T. M. et al. Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. BMJ 351, h4848 (2015).PubMedPubMedCentralCrossRef

94.

He, W., Phipps-Green, A., Stamp, L. K., Merriman, T. R. & Dalbeth, N. Population-specific association between ABCG2 variants and tophaceous disease in people with gout. Arthritis Res. Ther. 19, 43 (2017).PubMedPubMedCentralCrossRef

95.

Spiliopoulou, A. et al. Genomic prediction of complex human traits: relatedness, trait architecture and predictive meta-models. Hum. Mol. Genet. 24, 4167–4182 (2015).PubMedPubMedCentralCrossRef

96.

Wen, C. C. et al. Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response. Clin. Pharmacol. Ther. 97, 518–525 (2015).PubMedPubMedCentralCrossRef

97.

Roberts, R. L. et al. ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout. Pharmacogenomics J. 17, 201–203 (2017).PubMedCrossRef

98.

Wallace, M. C. et al. Association between ABCG2 rs2231142 and poor response to allopurinol: replication and meta-analysis. Rheumatology 57, 656–660 (2018).PubMedCrossRef

99.

Ichida, K. et al. Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion. J. Am. Soc. Nephrol. 15, 164–173 (2004).PubMedCrossRef

100.

Charles, B. A. et al. A genome-wide association study of serum uric acid in African Americans. BMC Med. Genomics 4, 17 (2011).PubMedPubMedCentralCrossRef

101.

Chittoor, G. et al. Genetic variation underlying renal uric acid excretion in Hispanic children: the Viva La Familia Study. BMC Med. Genet. 18, 6 (2017).PubMedPubMedCentralCrossRef

102.

Giri, A. K. et al. Genome wide association study of uric acid in Indian population and interaction of identified variants with type 2 diabetes. Sci. Rep. 6, 21440 (2016).PubMedPubMedCentralCrossRef

103.

Huffman, J. E. et al. Modulation of genetic associations with serum urate levels by body-mass-index in humans. PLoS ONE 10, e0119752 (2015).PubMedPubMedCentralCrossRef

104.

Kamatani, Y. et al. Genome-wide association study of hematological and biochemical traits in a Japanese population. Nat. Genet. 42, 210–215 (2010).PubMedCrossRef

105.

Karns, R. et al. Genome-wide association of serum uric acid concentration: replication of sequence variants in an island population of the Adriatic Coast of Croatia. Ann. Hum. Genet. 76, 121–127 (2012).PubMedPubMedCentralCrossRef

106.

Kenny, E. E. et al. Increased power of mixed models facilitates association mapping of 10 loci for metabolic traits in an isolated population. Hum. Mol. Genet. 20, 827–839 (2010).PubMedPubMedCentralCrossRef

107.

Kolz, M. et al. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet. 5, 1000504 (2009).CrossRef

108.

Korostishevsky, M. et al. Genomics and metabolomics of muscular mass in a community-based sample of UK females. Eur. J. Hum. Genet. 24, 277–283 (2016).PubMedCrossRef

109.

Li, S. et al. The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts. PLoS Genet. 3, e194 (2007).PubMedPubMedCentralCrossRef

110.

Li, W. D. et al. A genome wide association study of plasma uric acid levels in obese cases and never-overweight controls. Obesity 21, E490–E494 (2013).PubMedPubMedCentral

111.

McArdle, P. F. et al. Association of a common nonsynonymous variant in GLUT9 with serum uric acid levels in Old Order Amish. Arthritis Rheum. 58, 2874–2881 (2008).PubMedPubMedCentralCrossRef

112.

Middelberg, R. P. et al. Genetic variants in LPL, OASL and TOMM40/APOE-C1-C2-C4 genes are associated with multiple cardiovascular-related traits. BMC Med. Genet. 12, 123 (2011).PubMedPubMedCentralCrossRef

113.

Nagy, R. et al. Exploration of haplotype research consortium imputation for genome-wide association studies in 20,032 Generation Scotland participants. Genome Med. 9, 23 (2017).PubMedPubMedCentralCrossRef

114.

Merriman, T. R. et al. Trans-ancestral meta-analysis identifies 13 new loci associated with serum urate levels [abstract OP0263]. Ann. Rheum. Dis. 76 (Suppl. 2) 165 (2017).

115.

Son, C.-N. et al. ABCG2 polymorphism is associated with hyperuricemia in a study of a community-based Korean cohort. J. Korean Med. Sci. 32, 1451–1459 (2017).PubMedPubMedCentralCrossRef

116.

Suhre, K. et al. Human metabolic individuality in biomedical and pharmaceutical research. Nature 477, 54–60 (2011).PubMedCrossRef

117.

Voruganti, V. S. et al. Genome-wide association analysis confirms and extends the association of SLC2A9 with serum uric acid levels to Mexican Americans. Front. Genet. 4, 279 (2013).PubMedPubMedCentralCrossRef

118.

Wallace, C. et al. Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. Am. J. Hum. Genet. 82, 139–149 (2008).PubMedPubMedCentralCrossRef

119.

Yang, Q. O. et al. Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ. Cardiovasc. Genet. 3, 523–530 (2010).PubMedPubMedCentralCrossRef

120.

Zemunik, T. et al. Genome-wide association study of biochemical traits in Korčula Island, Croatia. Croat. Med. J. 50, 23–33 (2009).PubMedPubMedCentralCrossRef

121.

Yang, B. et al. A genome-wide association study identifies common variants influencing serum uric acid concentrations in a Chinese population. BMC Med. Genomics 7, 10 (2014).PubMedPubMedCentralCrossRef

122.

Reynolds, R. J. et al. Serum urate gene associations with incident gout, measured in the Framingham heart study, are modified by renal disease and not by body mass index. Rheumatol. Int. 36, 263–270 (2016).PubMedCrossRef

123.

Stark, K. et al. Common polymorphisms influencing serum uric acid levels contribute to susceptibility to gout, but not to coronary artery disease. PLoS ONE 4, e7729 (2009).PubMedPubMedCentralCrossRef

124.

Zhang, Y. et al. Associations of gout with polymorphisms in SLC2A9, WDR1, CLNK, PKD2, and ABCG2 Chinese Han and Tibetan populations. Int. J. Clin. Exp. Pathol. 9, 7503–7517 (2016).

125.

Zhou, Z. W. et al. Polymorphisms in GCKR, SLC17A1 and SLC22A12 were associated with phenotype gout in Han Chinese males: a case-control study. BMC Med. Genet. 16, 66 (2015).PubMedPubMedCentralCrossRef

126.

Zheng, C., Yang, H., Wang, Q., Rao, H. & Diao, Y. Association analysis of five SNP variants with gout in the Minnan population in China. Turk. J. Med. Sci. 46, 361–367 (2016).PubMedCrossRef

127.

Kim, Y. S. et al. Genetic analysis of ABCG2 and SLC2A9 gene polymorphisms in gouty arthritis in a Korean population. Korean J. Intern. Med. 30, 913–920 (2015).PubMedPubMedCentralCrossRef

128.

Wan, W., Xu, X., Zhao, D., Pang, Y. & Wang, Y. Polymorphisms of uric transporter proteins in the pathogenesis of gout in a Chinese Han population. Genet. Mol. Res. 14, 2546–2550 (2015).PubMedCrossRef

129.

Matsuo, H. et al. Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population. Sci. Transl. Med. 1, 5ra11 (2009).PubMedCrossRef

130.

Li, R. et al. A meta-analysis of the associations between the Q141K and Q126X gene variants and gout risk. Int. J. Clin. Exp. Pathol. 8, 9812–9823 (2015).PubMedPubMedCentral

131.

Sakiyama, M. et al. The effects of URAT1/SLC22A12 nonfunctional variants, R90H and W258X, on serum uric acid levels and gout/hyperuricemia progression. Sci. Rep. 6, 20148 (2016).PubMedPubMedCentralCrossRef

132.

Schunkert, H. et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat. Genet. 43, 333–338 (2011).PubMedPubMedCentralCrossRef

Medicine Matters Rheumatology

Abstract